EntrepreneurialCheck
Robert Schultz estimated net worth profile

Robert Schultz net worth

Robert Schultz Net Worth 2026 (Estimated) · Founder at Voyage Biomedical · YC S19
est. wealth $5.0M

Quick answer

Robert Schultz's estimated net worth is $5.0M (range $3.5M – $7.5M) as of 2026. Robert Schultz is Founder at Voyage Biomedical. Voyage Biomedical valuation.

Robert Schultz is Founder at Voyage Biomedical (YC S19). Independent Entrepreneurial Check model estimate from public YC data.

At a glance

NameRobert Schultz
RoleFounder
CompanyVoyage Biomedical
YC batchS19
Est. company val$100.0M
Assumed ownership5%
Est. paper wealth / net worth$5.0M
$3.5M – $7.5M
  • Company status: Acquired
  • Education: Stanford University
  • Region: Canada
  • Industries: Healthcare, Medical Devices
  • Team size: 3
  • Website: https://voyage.bio

Who is Robert Schultz?

Robert Schultz is a co-founder of Voyage Biomedical, a company that focuses on developing advanced technologies for healthcare applications. He was part of Y Combinator's Summer 2019 cohort.

Highlights:

  • Stanford University
  • Voyage Biomedical
  • Y Combinator S19

About Voyage Biomedical

Acquired by Penumbra (NYSE:PEN).

FAQ: Robert Schultz net worth and Voyage Biomedical valuation

What is Robert Schultz's net worth?

Robert Schultz's estimated net worth is $5.0M (range $3.5M – $7.5M) as of 2026. Robert Schultz is Founder at Voyage Biomedical. Entrepreneurial Check publishes an independent model-based estimate from public company and role data. Not verified net worth, and Entrepreneurial Check is not affiliated with Y Combinator or the profiled companies.

What is Voyage Biomedical valuation?

Voyage Biomedical's estimated valuation on Entrepreneurial Check is $100.0M. That valuation, or a disclosed round when one is public, is the source for the paper-wealth estimate. Independent model output — not a verified appraisal or official mark.

What is Robert Schultz's role?

Robert Schultz is Founder at Voyage Biomedical, a Y Combinator-backed startup (batch S19).